Brief: Biophytis SA Announces Design Of Its Phase 2 Oba Clinical Study In Obesity
14/05/2024 15:47
May 14 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS SA - ANNOUNCES DESIGN OF ITS PHASE 2 OBA CLINICAL STUDY IN OBESITY
* BIOPHYTIS SA - BIOPHYTIS IS PREPARING FOR FILING AN INVESTIGATIONAL NEW DRUG (IND) TO
START OBA
PHASE 2 STUDY IN USA IN COMING WEEKS
* BIOPHYTIS SA - OBA PHASE 2 CLINICAL STUDY IS EXPECTED TO START MID 2024, UPON REGULATORY
APPROVALS
* BIOPHYTIS SA - FIRST RESULTS OF SAFETY AND EFFICACY OF BIO101 (20-HYDROXYECDYSONE) DRUG
CANDIDATE ARE EXPECTED TO BE AVAILABLE IN 2025
Source text for Eikon: ID:n0001104659-24-060968
Further company coverage: ALBPS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon